Go Pro
NASDAQ:SGP

Spyglass Pharma Q1 2026 Earnings Report

Spyglass Pharma logo
$29.08 -0.25 (-0.85%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$29.02 -0.05 (-0.19%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Spyglass Pharma EPS Results

Actual EPS
-$0.69
Consensus EPS
-$0.67
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Spyglass Pharma Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Spyglass Pharma Announcement Details

Quarter
Q1 2026
Time
After Market Closes
Conference Call Date
Thursday, May 14, 2026
Conference Call Time
4:00PM ET

Spyglass Pharma Earnings Headlines

Spyglass Pharma (NASDAQ:SGP) Rating Increased to Hold at Wall Street Zen
Your book attached
Bill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.tc pixel
See More Spyglass Pharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Spyglass Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Spyglass Pharma and other key companies, straight to your email.

About Spyglass Pharma

Spyglass Pharma (NASDAQ:SGP) is a clinical-stage ophthalmic pharmaceutical company focused on developing long-acting treatments for chronic eye diseases. The company is developing drug-delivery technologies intended to reduce the need for patients to administer topical eye drops regularly.

Its lead development program, SGP-310, is an intraocular implant designed to provide sustained delivery of travoprost, a prostaglandin analog used to lower elevated intraocular pressure. The product is being developed for patients with primary open-angle glaucoma or ocular hypertension, conditions that can increase the risk of vision loss if left untreated.

SpyGlass Pharma’s platform is intended to support extended drug release inside the eye, potentially improving treatment consistency and adherence compared with daily topical medications. The company is headquartered in Irvine, California, and its activities are primarily focused on ophthalmic drug development and clinical research. Further information about its commercial operations and geographic reach is limited because the company remains in the development stage.

View Spyglass Pharma Profile